Medline Inc.
MDLNHealthcareNASDAQMedical Instruments & Supplies · Last scanned Oct 26, 2026
Scan Results
Daily timeframeMedline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally. The company carries a $45.87B market cap, placing it firmly in the large-cap category. It operates through two segments: Medline Brand and Supply Chain Solutions.
Market Cap
$45.87B
Beta
—
P/E (TTM)
87.41
P/E (Fwd)
21.72
EPS (TTM)
$0.39
EPS (Fwd)
$1.57
ROE
4.9%
ROA
2.5%
Cash
$2.70B
Total Debt
$12.64B
Free CF
$850.6M
52W Change
-16.9%
Annual Financials
Cash vs Debt
Where MDLN stands vs its 150-day and 200-day moving averages
As of the October 16, 2026 close, MDLN finished 5.19% below its 150-day moving average ($38.57) and 8.69% below its 200-day moving average ($40.05). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is MDLN overbought or oversold?
At the October 16, 2026 close, MDLN's RSI(14) was 71.1, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $2.70B in cash, though total debt stands at $12.64B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company generates $850.6M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 4.9%, which is modest for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 2.5% is on the lower side, which is common in asset-heavy industries.
At over 50x earnings, MDLN carries valuation risk — any slowdown in growth expectations could lead to meaningful price adjustments. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing MDLN.